Aug 6, 2026
Novo Nordisk reported quarterly results that beat expectations and raised guidance, but shares fell as investors remained concerned about the company's path to sustainable growth amid increasing competition in the obesity drug market.
Novo Nordisk's experimental inflammation-targeting drug failed to reduce the risk of heart attacks and strokes in a closely watched large clinical trial, a setback for the drugmaker's growth prospects beyond obesity and diabetes.
India's drug regulator approved Novo Nordisk's obesity drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease, expanding the drug's approved uses beyond weight loss.
Novo Nordisk's stock price and earnings received a boost following less-negative news about the development of an oral version of its blockbuster weight loss drug Wegovy, marking progress in the company's efforts to create a pill formulation.
France's medicines regulator has imposed fines on Novo Nordisk and Eli Lilly for their weight loss drug advertising campaigns, marking a significant regulatory action against the pharmaceutical giants' marketing practices.